Drug Profile
xl 130
Alternative Names: PAS-IL1Ra; xl-130Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator XL-protein GmbH
- Class Anti-inflammatories
- Mechanism of Action Interleukin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Inflammation
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Inflammation in Germany
- 09 Aug 2016 xl 130 is available for licensing as of 09 Aug 2016. http://www.xl-protein.com/
- 09 Aug 2016 Early research in Inflammation in Germany (unspecified route)